Technology ID
TAB-4486

Real-time Monitoring of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine as a Diagnostic and Disease Monitoring Tool

E-Numbers
E-069-2020-0
Lead Inventor
Cherukuri, Murali (National Cancer Institute (NCI))
Co-Inventors
Swenson, Rolf (NHLBI)
Yamamoto, Kazutoshi (National Cancer Institute (NCI))
Opina, Ana (NHLBI)
Applications
Research Materials
Diagnostics
Therapeutic Areas
Oncology
Neurology
Development Stages
Pre-clinical (in vivo)
Lead IC
NHLBI
ICs
NHLBI

This technology includes synthesized demonstrated [1-13C] NAC as a promising novel probe for hyperpolarized 13C MRI methodologies which could provide diagnostic, and evaluation of response to treatment in various cancers and neurological diseases. N-acetyl cysteine (NAC) is a widely used therapeutic and involved to stimulate glutathione synthesis. Glutathione elevates detoxification and works directly as a free radical scavenger. In vivo hyperpolarized NAC was broadly distributed throughout the body. The chemical conversions into products were observed in pancreatic tumor xenografts, Hs766t, and SU.86.86, with various conversion efficiencies depending on metabolic characteristics and status. Hyperpolarized NAC can provide insights into redox status, metabolic profile, and enzymatic activities.

Commercial Applications
Monitoring the antioxidation and enzymatic status could provide diagnostic, and evaluation of response to treatment in various cancers and neurological diseases.

Competitive Advantages
The ability to cross the blood brain barrier is a substantial benefit of this agent.

Request More Info

Licensing Contact:
Shmilovich, Michael
shmilovm@nih.gov

Collaborations

  • Licensing

Collaboration Description

  • We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology.
Date Published